Emmanuelle Quiles

Emmanuelle Quilès holds a Degree of Biotechnological Engineer from Strasbourg University. Emmanuelle began her career as a clinical research associate first at Rhône-Poulenc, then at Pierre Fabre and then at Genetics Institute until Wyeth bought the company. 

Emmanuelle then held marketing positions in the Hemophilia field, she evolved into increasingly important roles in various fields (anti-infectives, oncology, neurology) until she was appointed head of Wyeth's largest franchise, the Rheumatology and Dermatology Business Unit. In November 2007, Emmanuelle was appointed CEO of Wyeth France and, after Pfizer's acquisition, she was confirmed as President of Pfizer France. In December 2012, she left Pfizer to set up Harmonium, a European start-up specialized in diabetology. She was appointed President of Janssen France on January 5th, 2015. Since 2019, she has been a member of the GIP Génopole's Industry Science Innovation Committee, the President of the “Artificial Intelligence and Heath” programme within the Strategic Committee for Health Industries and Technologies and a member of Business France Board. She is a Knight of the Legion of Honor.